Although significant research data exist on the pathophysiology of nonalcoholic
steatohepatitis (NASH), finding an efficient treatment regimen for it remains elusive. The
present study used sparstolonin B (SsnB), a novel TLR4 antagonist derived from the
Chinese herb Sparganium stoloniferum, as a possible drug to mitigate early inflammation in
NASH. This study used an early steatohepatitic injury model in high-fat-fed mice with
CYP2E1-mediated oxidative stress as a second hit. SsnB was administered for 1 wk along …

Although significant research data exists about the pathophysiology of Nonalcoholic 28
Steatohepatitis (NASH), finding an efficient treatment regimen for it remains elusive. 29 The
present study used Sparstolonin B (SsnB), novel TLR4 antagonist derived from 30 Chinese
herb Spaganium stoloniferum as a possible drug to mitigate early inflammation 31 in NASH.
This study uses an early steatohepatitic injury model in high fat fed mice with 32 CYP2E1-
mediated oxidative stress as a second hit. SsnB was administered for 1 week 33 along with …